Status:
COMPLETED
Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Graft vs Host Disease
Cutaneous Sclerosis
Eligibility:
All Genders
Brief Summary
The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.
Detailed Description
Allogeneic hematopoietic cell transplantation (HCT) is the only known curative option for many hematologic disorders. After transplantation, many patients develop immune mediated disorders that may be...
Eligibility Criteria
Inclusion
- Planned or completed first allogeneic stem cell transplant (any conditioning regimen, graft source, donor type and GVHD prophylaxis regimen)
- Signed, informed consent and, if applicable, child assent
Exclusion
- Inability to comply with study procedures
- Anticipated survival less than 6 months due to co-morbid disease
- Autoimmune disorder or inherited immunodeficiency before HCT
- Diagnosis of late acute or chronic GVHD prior to study enrollment
- Hematologic relapse or chemotherapy refractory disease at restaging within 1 month of HCT or at the time of enrollment (e.g., \> 5% blasts for leukemia; poorly responsive lymphoma)
Key Trial Info
Start Date :
March 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2016
Estimated Enrollment :
911 Patients enrolled
Trial Details
Trial ID
NCT01206309
Start Date
March 1 2011
End Date
October 1 2016
Last Update
October 7 2016
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Scottsdale, Arizona, United States, 85054
2
Stanford University
Stanford, California, United States, 94305
3
H. Lee Moffitt Cancer Center
Tampa, Florida, United States, 33612
4
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115